Search for a clinical trial
25 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trials
AUSTRIA
TIROL
INNSBRUCK
MOXIe: A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia - AT
Medizinische Universität Innsbruck
Universitätsklinik für Neurologie
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Six-Month Double-Blind, Randomized, Placebo-Controlled Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia (Phase I-II) ) -Completed
Erasme Hospital - ULB
Clinique de Génétique Médicale
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients (MICONOS).
Erasme Hospital - ULB
Clinique de Génétique Médicale
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia (Phase II).
Erasme Hospital - ULB
Clinique de Génétique Médicale
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients (MICONOS Extension).
Erasme Hospital - ULB
Clinique de Génétique Médicale
FRANCE
ILE-DE-FRANCE
PARIS
Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II
CHU Paris - Hôpital Necker-Enfants Malades
Laboratoire de Génétique Moléculaire
FRANCE
ILE-DE-FRANCE
PARIS
A Six-Month Double-Blind, Randomized, Placebo-Controlled Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia (Phase I-II)
CHU Paris - Hôpital Necker-Enfants Malades
Laboratoire de Génétique Moléculaire
FRANCE
ILE-DE-FRANCE
PARIS
An Open-Label, Single Treatment, Safety and Efficacy, Long-Term Study of Deferiprone in Subjects With Friedreich's Ataxia (Phase II)
CHU Paris - Hôpital Necker-Enfants Malades
Laboratoire de Génétique Moléculaire
FRANCE
ILE-DE-FRANCE
PARIS
Effect of pioglitazone administered to patients with Friedreich's ataxia : proof of concept (Phase II)
CHU Paris - Hôpital Robert Debré
Service de neurologie pédiatrique et des maladies métaboliques
FRANCE
ILE-DE-FRANCE
PARIS
SNT-III-001 MICONOS. A Phase III double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of Idebenone in the treatment of Friedreich Ataxia
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Equipe "Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives"
FRANCE
ILE-DE-FRANCE
PARIS
MICONOS Extension : A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients - FR
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Equipe "Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives"
GERMANY
Nordrhein-Westfalen
AACHEN
SNT-III-001(MICONOS): A Phase III double-blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of Idebenone in the treatment of Friedreich Ataxia patients - Terminated
Universitätsklinikum Aachen
GeNeMove - Netzwerksekretariat
GERMANY
Nordrhein-Westfalen
AACHEN
SNT-III-001-E (MICONOS Extension):A Phase III open-label, single-group, extension study to obtain long-term safety and tolerability data of Idebenone in the treatment of Friedreich Ataxia patients - DE
Universitätsklinikum Aachen
GeNeMove - Netzwerksekretariat
ITALY
CAMPANIA
NAPOLI
Pilot study for the evaluation of the efficacy tolerability of the erithropoietine in patients affected by Friedreich's Ataxia
Azienda Ospedaliera Universitaria "Federico II"
Dipartimento di Scienze Neurologiche
ITALY
LOMBARDIA
MILANO
A Six-Month Double-Blind, Randomized, Placebo-Controlled Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia
Fondazione IRCCS Istituto Neurologico "Carlo Besta"
U.O. Biochimica e Genetica
SPAIN
Madrid
MADRID
A Six-Month Double-Blind, Randomized, Placebo-Controlled Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia (Phase I-II) (completed)
Hospital Universitario La Paz
Fundación para la Investigación Biomédica
SPAIN
Madrid
MADRID
An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia (Phase II) (completed)
Hospital Universitario La Paz
Fundación para la Investigación Biomédica
UNITED KINGDOM
Greater London
LONDON
Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in FRDA (Phase II)
Hammersmith Hospital
Gene Control Mechanisms and Disease Research Group
UNITED KINGDOM
Greater London
LONDON
A six-month double-blind, randomized, placebo-controlled study investigating the safety and tolerability of deferiprone in participants with Friedreich's ataxia (Phase I-II) - UK
Royal Free Hospital
Department of Neurosciences
UNITED KINGDOM
Greater Manchester
NOT YET IDENTIFIED - UK
MICONOS Extension : A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients - UK
NOT YET IDENTIFIED - UK
UNITED KINGDOM
Norfolk
NORWICH
An investigation of the effectiveness of Lycra pressure garments in the management of movement control problems caused by Cerebellar Ataxia (Phase III)
Norfolk and Norwich University Hospital
Neurology Department
AUSTRIA
TIROL
INNSBRUCK
ALCAT: Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial - AT
Medizinische Universität Innsbruck
Universitätsklinik für Neurologie
ITALY
LAZIO
ROMA
Effect of riluzole as a symptomatic approach in patients with chronic cerebellar ataxia
A.O. S. Andrea
U.O.C. di Neurologia
Multinational clinical trials
CANADA
Ontario
WESTON
An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia (Phase II) (coordination)
Apotex Inc.
ApoPharma Inc.
CANADA
Ontario
WESTON